Cargando…
A CRISPR/CAS9‐based strategy targets the personalized chimeric neosequence in fusion‐driven cancer genome for precision medicine
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967915/ https://www.ncbi.nlm.nih.gov/pubmed/33783997 http://dx.doi.org/10.1002/ctm2.355 |
| _version_ | 1783665969607999488 |
|---|---|
| author | Huang, Wei Zeng, Zhan‐Cheng Wang, Wen‐Tao Sun, Yu‐Meng Chen, Yue‐Qin Luo, Xue‐Qun Fang, Ke |
| author_facet | Huang, Wei Zeng, Zhan‐Cheng Wang, Wen‐Tao Sun, Yu‐Meng Chen, Yue‐Qin Luo, Xue‐Qun Fang, Ke |
| author_sort | Huang, Wei |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7967915 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79679152021-03-19 A CRISPR/CAS9‐based strategy targets the personalized chimeric neosequence in fusion‐driven cancer genome for precision medicine Huang, Wei Zeng, Zhan‐Cheng Wang, Wen‐Tao Sun, Yu‐Meng Chen, Yue‐Qin Luo, Xue‐Qun Fang, Ke Clin Transl Med Letter to Editor John Wiley and Sons Inc. 2021-03-17 /pmc/articles/PMC7967915/ /pubmed/33783997 http://dx.doi.org/10.1002/ctm2.355 Text en © 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to Editor Huang, Wei Zeng, Zhan‐Cheng Wang, Wen‐Tao Sun, Yu‐Meng Chen, Yue‐Qin Luo, Xue‐Qun Fang, Ke A CRISPR/CAS9‐based strategy targets the personalized chimeric neosequence in fusion‐driven cancer genome for precision medicine |
| title | A CRISPR/CAS9‐based strategy targets the personalized chimeric neosequence in fusion‐driven cancer genome for precision medicine |
| title_full | A CRISPR/CAS9‐based strategy targets the personalized chimeric neosequence in fusion‐driven cancer genome for precision medicine |
| title_fullStr | A CRISPR/CAS9‐based strategy targets the personalized chimeric neosequence in fusion‐driven cancer genome for precision medicine |
| title_full_unstemmed | A CRISPR/CAS9‐based strategy targets the personalized chimeric neosequence in fusion‐driven cancer genome for precision medicine |
| title_short | A CRISPR/CAS9‐based strategy targets the personalized chimeric neosequence in fusion‐driven cancer genome for precision medicine |
| title_sort | crispr/cas9‐based strategy targets the personalized chimeric neosequence in fusion‐driven cancer genome for precision medicine |
| topic | Letter to Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967915/ https://www.ncbi.nlm.nih.gov/pubmed/33783997 http://dx.doi.org/10.1002/ctm2.355 |
| work_keys_str_mv | AT huangwei acrisprcas9basedstrategytargetsthepersonalizedchimericneosequenceinfusiondrivencancergenomeforprecisionmedicine AT zengzhancheng acrisprcas9basedstrategytargetsthepersonalizedchimericneosequenceinfusiondrivencancergenomeforprecisionmedicine AT wangwentao acrisprcas9basedstrategytargetsthepersonalizedchimericneosequenceinfusiondrivencancergenomeforprecisionmedicine AT sunyumeng acrisprcas9basedstrategytargetsthepersonalizedchimericneosequenceinfusiondrivencancergenomeforprecisionmedicine AT chenyueqin acrisprcas9basedstrategytargetsthepersonalizedchimericneosequenceinfusiondrivencancergenomeforprecisionmedicine AT luoxuequn acrisprcas9basedstrategytargetsthepersonalizedchimericneosequenceinfusiondrivencancergenomeforprecisionmedicine AT fangke acrisprcas9basedstrategytargetsthepersonalizedchimericneosequenceinfusiondrivencancergenomeforprecisionmedicine AT huangwei crisprcas9basedstrategytargetsthepersonalizedchimericneosequenceinfusiondrivencancergenomeforprecisionmedicine AT zengzhancheng crisprcas9basedstrategytargetsthepersonalizedchimericneosequenceinfusiondrivencancergenomeforprecisionmedicine AT wangwentao crisprcas9basedstrategytargetsthepersonalizedchimericneosequenceinfusiondrivencancergenomeforprecisionmedicine AT sunyumeng crisprcas9basedstrategytargetsthepersonalizedchimericneosequenceinfusiondrivencancergenomeforprecisionmedicine AT chenyueqin crisprcas9basedstrategytargetsthepersonalizedchimericneosequenceinfusiondrivencancergenomeforprecisionmedicine AT luoxuequn crisprcas9basedstrategytargetsthepersonalizedchimericneosequenceinfusiondrivencancergenomeforprecisionmedicine AT fangke crisprcas9basedstrategytargetsthepersonalizedchimericneosequenceinfusiondrivencancergenomeforprecisionmedicine |